Reach Us +44-1764-910199
Advances in ALK Targeted Therapy for Neuroblastoma | OMICS International | Abstract
ISSN: 2476-2261

Journal of Oncology Translational Research
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Review Article

Advances in ALK Targeted Therapy for Neuroblastoma

Libo Zhang1,2* and Sylvain Baruchel3,4

1Department of Molecular Medicine, The Hospital for Sick Children, Toronto, Canada

2Department of Anesthesia, The Hospital for Sick Children, Toronto, Canada

3Deptartment of Pediatrics, The Hospital for Sick Children, Toronto, Canada

4Institute of Medical Sciences, University of Toronto, Toronto, Canada

*Corresponding Author:
Sylvain Baruchel
Innovative Therapeutic Trials Office
Dept. of Pediatrics and Research Institute
The Hospital for Sick Children, 555 University Avenue
Toronto, Ontario, Canada M5G 1X8
Tel: 416-813-7795
Fax: 416-813-5327
E-mail: [email protected]

Received date: July 27, 2017; Accepted date: July 27, 2017; Published date: August 03, 2017

Citation: Zhang L, Baruchel S (2017) Advances in ALK Targeted Therapy for Neuroblastoma. J Oncol Transl Res 3:114. doi:10.4172/2476-2261.1000114

Copyright: © 2017 Zhang L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Significant advances have been made to understand the association between ALK genetic aberrations and disease prognosis in neuroblastoma. ALK targeted therapies are evolving quickly and several randomized controlled trials of ALK inhibitors are underway or nearing completion in adult cancers. Ongoing research will bring new challenges and newer technologies to fully define the pathogenic and prognostic alterations, to stratify the risk of recurrence or progression, and to develop optimal monitoring and treatment strategies in this malignancy.


Leave Your Message 24x7